NCT01957449

Brief Summary

To determine the safety and efficacy of administration of propranolol for reducing heart rate and blood pressure in burn injury.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Dec 2013

Longer than P75 for phase_2

Geographic Reach
1 country

4 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 4, 2013

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 8, 2013

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 23, 2019

Completed
Last Updated

September 24, 2019

Status Verified

August 1, 2018

Enrollment Period

5 years

First QC Date

September 4, 2013

Last Update Submit

September 20, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Resting heart rate multiplied by the systolic blood pressure measurement= rate pressure product

    Multiply the subjects resting heart rate and systolic blood pressure measurements and average every 24 hours while hospitalized (an average of 4 weeks)

    Measured during acute hospital stay, an average of 4 weeks.

Secondary Outcomes (1)

  • Number of deaths

    time of randomization up to one year

Study Arms (2)

Propranolol

ACTIVE COMPARATOR

Propranolol by mouth given daily throughout hospitalization for up to 12 months

Drug: Propranolol

Sugar Pill

PLACEBO COMPARATOR

Placebo by mouth given daily throughout hospitalization for up to 12 months

Drug: Placebo

Interventions

Propranolol by mouth given daily throughout hospitalization for up to 12 months

Also known as: Metoprolol, inderal
Propranolol

Placebo by mouth given daily throughout hospitalization for up to 12 months.

Also known as: Control
Sugar Pill

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Burns covering \>20% of the total body surface are
  • Age of 0 to 18 years
  • Patient arrival to the burn center within 96 hours (4 days) of burn injury
  • Require \> 1 surgical procedure

You may not qualify if:

  • Pregnancy
  • Known history of AIDS, Aids Related Complex, or HIV
  • History of cancer within 5 years
  • Existence of pre-morbid conditions
  • Asthma
  • Congestive heart failure (measured ejection fraction \< 20%)
  • Medical condition requiring glucocorticoid treatment
  • Burn injury due to chemical burns
  • Burn injury due to deep electrical injury (decision of hospital PI)
  • Presence of anoxic brain injury that is not expected to result in complete recovery
  • Decision not to treat due to burn injury severity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Shriners Hospitals for Children

Sacramento, California, 95817, United States

Location

Shriners Hospitals for Children

Boston, Massachusetts, 02114, United States

Location

Shriners Hospitals for Children

Cincinnati, Ohio, 45229, United States

Location

Shriners Hospitals for Children

Galveston, Texas, 77551, United States

Location

MeSH Terms

Conditions

Burns

Interventions

PropranololMetoprolol

Condition Hierarchy (Ancestors)

Wounds and Injuries

Intervention Hierarchy (Ancestors)

PhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic Compounds

Study Officials

  • David N Herndon, MD

    University of Texas

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 4, 2013

First Posted

October 8, 2013

Study Start

December 1, 2013

Primary Completion

December 1, 2018

Study Completion

April 23, 2019

Last Updated

September 24, 2019

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations